Wall Street analysts expect BeiGene (NASDAQ:BGNE) to post sales of $15.84 million for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for BeiGene’s earnings, with the lowest sales estimate coming in at $15.00 million and the highest estimate coming in at $16.83 million. The business is scheduled to issue its next earnings report on Wednesday, May 9th.
On average, analysts expect that BeiGene will report full-year sales of $115.34 million for the current financial year, with estimates ranging from $69.37 million to $203.60 million. For the next fiscal year, analysts anticipate that the firm will post sales of $142.63 million per share, with estimates ranging from $73.10 million to $327.32 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that follow BeiGene.
BeiGene (NASDAQ:BGNE) last announced its earnings results on Wednesday, February 28th. The company reported ($2.19) EPS for the quarter, missing the consensus estimate of ($1.79) by ($0.40). The business had revenue of $18.17 million for the quarter, compared to analysts’ expectations of $23.00 million.
In related news, EVP Ji Li sold 10,000 shares of the firm’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $146.88, for a total value of $1,468,800.00. Following the completion of the transaction, the executive vice president now directly owns 10,000 shares of the company’s stock, valued at $1,468,800. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Howard Liang sold 40,000 shares of the firm’s stock in a transaction on Monday, March 19th. The shares were sold at an average price of $160.27, for a total transaction of $6,410,800.00. Following the completion of the transaction, the chief financial officer now directly owns 15,872 shares of the company’s stock, valued at $2,543,805.44. The disclosure for this sale can be found here. Insiders sold 194,210 shares of company stock valued at $29,041,676 over the last three months. 19.90% of the stock is owned by company insiders.
Large investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC bought a new position in shares of BeiGene in the fourth quarter valued at $182,000. Comerica Bank bought a new position in shares of BeiGene in the fourth quarter valued at $246,000. Mackenzie Financial Corp bought a new position in shares of BeiGene in the fourth quarter valued at $250,000. Jefferies Group LLC bought a new position in shares of BeiGene in the fourth quarter valued at $283,000. Finally, Virtus Fund Advisers LLC bought a new position in shares of BeiGene in the fourth quarter valued at $365,000. 51.47% of the stock is owned by institutional investors and hedge funds.
Shares of BGNE opened at $167.99 on Friday. The company has a market cap of $9,059.45, a PE ratio of -75.33 and a beta of 0.23. BeiGene has a twelve month low of $34.36 and a twelve month high of $182.79. The company has a debt-to-equity ratio of 0.23, a current ratio of 6.09 and a quick ratio of 6.02.
ILLEGAL ACTIVITY WARNING: “BeiGene (BGNE) Expected to Post Quarterly Sales of $15.84 Million” was first posted by Week Herald and is owned by of Week Herald. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://weekherald.com/2018/04/21/beigene-bgne-expected-to-post-quarterly-sales-of-15-84-million.html.
BeiGene Company Profile
BeiGene, Ltd., a clinical-stage biopharmaceutical company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.